The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Buianova S.N.
Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii
Shchukina N.A.
Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii
Babunashvili E.L.
Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia
Biological role and therapeutic potential of phytoflavonoids and vitamin D in the treatment of patients with uterine myoma, as well as other promising pharmacological directions
Journal: Russian Bulletin of Obstetrician-Gynecologist. 2018;18(5): 36‑42
Views: 10022
Downloaded: 153
To cite this article:
Buianova SN, Shchukina NA, Babunashvili EL. Biological role and therapeutic potential of phytoflavonoids and vitamin D in the treatment of patients with uterine myoma, as well as other promising pharmacological directions. Russian Bulletin of Obstetrician-Gynecologist.
2018;18(5):36‑42. (In Russ.)
https://doi.org/10.17116/rosakush20181805136
The review of the results of researches made in recent years presents new approaches to treating patients with uterine myoma. Numerous studies confirm that there is a clear pathophysiological basis for the use of phytoflavonoids to treat uterine myoma, which is extremely promising. Scientists have shown a clear relationship between the lower plasma level of vitamin D and the higher risk for uterine leiomyoma, as well as its protective role in the development of this disease. In view of the enormous importance of fibrogenesis in the pathophysiology of uterine leiomyoma, there is a continuing search for an effective antifibrotic medication for additional pathogenetic therapy. Pharmacological studies aimed to design thermosensitive nanomaterials (nanoparticles) as a depot for various drugs are promising. The accurate, controlled administration of the drug into the lesion area, including in uterine myoma, will provide its long-term delay and prevent premature inactivation, which will reduce the frequency of drug administration. The new approaches to pharmacotherapy for patients with uterine myoma can substantially enhance the efficiency of treatment and minimize the number of adverse effects.
Keywords:
Authors:
Buianova S.N.
Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii
Shchukina N.A.
Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii
Babunashvili E.L.
Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.